FDA Inspection 1123056 — Labcorp Drug Development

Labcorp Drug Development — FEI 2242945

The FDA completed an inspection of Labcorp Drug Development on Mar 5, 2020 in Princeton, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.

Inspection details

Classification
No Action Indicated (NAI)
End Date
Mar 5, 2020
Fiscal Year
2020
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Princeton, NJ (United States)

Additional details

Sponsor, Contract Research Organization

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.